GB202011154D0 - Use of cannabidiol in the treatment of seizures associated with encephaltis - Google Patents

Use of cannabidiol in the treatment of seizures associated with encephaltis

Info

Publication number
GB202011154D0
GB202011154D0 GBGB2011154.8A GB202011154A GB202011154D0 GB 202011154 D0 GB202011154 D0 GB 202011154D0 GB 202011154 A GB202011154 A GB 202011154A GB 202011154 D0 GB202011154 D0 GB 202011154D0
Authority
GB
United Kingdom
Prior art keywords
encephaltis
cannabidiol
treatment
seizures associated
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2011154.8A
Other versions
GB2597307A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB2011154.8A priority Critical patent/GB2597307A/en
Publication of GB202011154D0 publication Critical patent/GB202011154D0/en
Priority to PCT/EP2021/069905 priority patent/WO2022017963A1/en
Publication of GB2597307A publication Critical patent/GB2597307A/en
Pending legal-status Critical Current

Links

GB2011154.8A 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with encephalitis Pending GB2597307A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2011154.8A GB2597307A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with encephalitis
PCT/EP2021/069905 WO2022017963A1 (en) 2020-07-20 2021-07-15 Use of cannabidiol in the treatment of seizures associated with encephalitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2011154.8A GB2597307A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with encephalitis

Publications (2)

Publication Number Publication Date
GB202011154D0 true GB202011154D0 (en) 2020-09-02
GB2597307A GB2597307A (en) 2022-01-26

Family

ID=72338961

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2011154.8A Pending GB2597307A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with encephalitis

Country Status (2)

Country Link
GB (1) GB2597307A (en)
WO (1) WO2022017963A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Also Published As

Publication number Publication date
WO2022017963A1 (en) 2022-01-27
GB2597307A (en) 2022-01-26

Similar Documents

Publication Publication Date Title
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
IL274633A (en) Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
IL284758A (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB201907283D0 (en) Use of cannabidiol in the treatment of epileptic spams
GB2581987B (en) Use of cannabidiol in combination with antibiotics
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
GB202019301D0 (en) Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
GB202014723D0 (en) Use of cannabinoids in the treatment of epilepsy
IL286334A (en) Modified micrornas and their use in the treatment of cancer
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
GB201915522D0 (en) Use of cannabidiol preparations in the treatment of absence epilepsy
EP3302464A4 (en) Use of cannabinoids in the treatment of ocular inflammation and/or pain
EP3710010A4 (en) Use of hm4di in the treatment of seizure disorders
GB201915519D0 (en) Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB202011154D0 (en) Use of cannabidiol in the treatment of seizures associated with encephaltis
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB202102010D0 (en) Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
GB202011148D0 (en) Use of cannabidiol in the treatment of seizures associated with herpes simplex virus